Skip to main content
OpenTrials
Completed

NCT Number: NCT02194270

Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female Volunteers

Study to investigate the relative bioavailability of ambroxol hydrochloride soft pastilles 15 mg vs. ambroxol hydrochloride (HCL) 15 mg of syrup (15mg/5mL, Reference I) and ambroxol hydrochloride 15 mg of syrup (30mg/5mL, Reference II) in a fasted state

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests
  • No finding deviating from normal and of clinical relevance
  • No evidence of a clinically relevant concomitant disease
  • Age ≥18 and Age ≤55 years
  • BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
  • Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion criteria

  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  • Participation in another trial with an investigational drug within two months prior to administration or during the trial
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of study centre

For female subjects:

  • Pregnancy
  • Positive pregnancy test
  • No adequate contraception e.g. oral contraceptives, sterilization, intrauterine device (IUD)
  • Inability to maintain this adequate contraception during the whole study period
  • Lactation period

Treatment and study plan

Ambroxol hydrochloride - soft pastille

Drug

Ambroxol hydrochloride - syrup - low dose

Drug

Ambroxol hydrochloride - syrup - high dose

Drug

Primary outcomes

  1. AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: up to 30 hours after each drug administration

  2. Cmax (maximum concentration of the analyte in plasma)

    Time frame: up to 30 hours after each drug administration

Secondary outcomes

  1. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)

    Time frame: up to 30 hours after each drug administration

  2. tmax (time from dosing to the maximum concentration of the analyte in plasma)

    Time frame: up to 30 hours after each drug administration

  3. λz (terminal rate constant in plasma)

    Time frame: up to 30 hours after each drug administration

  4. t1/2 (terminal half-life of the analyte in plasma)

    Time frame: up to 30 hours after each drug administration

  5. MRTpo (mean residence time of the analyte in the body after p.o. (oral) administration)

    Time frame: up to 30 hours after each drug administration

  6. CL/F (apparent clearance of the analyte in the plasma after extravascular administration)

    Time frame: up to 30 hours after each drug administration

  7. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)

    Time frame: up to 30 hours after each drug administration

  8. Number of patients with adverse events

    Time frame: up to 40 days

  9. Number of patients with abnormal changes in laboratory parameters

    Time frame: up to 40 days

  10. Number of patients with clinically significant changes in vital signs (BP (Blood pressure), PR (Pulse rate))

    Time frame: up to 40 days

  11. Assessment of tolerability by investigator on a 4-point scale

    Time frame: within 8 days after last administration

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Relative Bioavailability of Ambroxol Hydrochloride Following Oral Administration of Soft Pastilles 15 mg (Test) Compared to 15 mg of Syrup (15mg/5mL, Reference I) and Compared to 15 mg of Syrup (30mg/5mL) (Reference II) in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, 3-way Crossover Study

Important dates

Study start
2004
Primary completion
2005
First posted
Jul 18, 2014
Registry last updated
Jul 18, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.